Verification note (checked 2026-07-16): SBIR/STTR reauthorization is a live legislative topic, and the specific dates, bill numbers, and provisions below were checked this session across the Small Business & Entrepreneurship Committee’s own bill-summary materials, the enacted 2022 extension’s public law text, NIH’s own program notice, and multiple independent government-contracts law firm client alerts, which converge on the same facts. Congress.gov itself returned an access error to automated fetching during this research (a known, recurring pattern for congress.gov and grants.nih.gov noted elsewhere on this site) — if a specific date or provision below is load-bearing for an institutional decision, confirm it directly against congress.gov’s S. 3971 bill page or sbir.gov before relying on it, and re-check this page’s currency if you’re reading it more than a few months after publication.
What “SBIR/STTR reauthorization” means
The Small Business Innovation Research (SBIR) program and its companion Small Business Technology Transfer (STTR) program are not permanent, standing federal programs the way most research grant mechanisms are. Both operate under statutory authority that Congress grants for a fixed number of years and must periodically renew, or “reauthorize,” before it expires. When that authority lapses without a renewal already in place, participating federal agencies lose their legal authority to issue new SBIR/STTR solicitations or make new SBIR/STTR awards until Congress acts again — even though the underlying set-aside requirement (agencies with extramural R&D budgets above a statutory threshold must direct a fixed percentage of that budget to SBIR, and a smaller percentage to STTR) has existed continuously since the programs were created.
This structure traces back to how each program was established: SBIR was created by the Small Business Innovation Development Act of 1982 (Public Law 97-219), and STTR was created a decade later by the Small Business Technology Transfer Act of 1992. Neither statute made the programs permanent — each reauthorization since has renewed the underlying authority for a defined term (commonly a several-year window) rather than removing the sunset provision altogether. That is a deliberate congressional choice, not an oversight: periodic reauthorization gives Congress a recurring point to revisit program rules, set-aside percentages, and eligibility requirements, but it also means the programs are structurally exposed to a lapse any time reauthorizing legislation doesn’t pass before the prior authorization’s expiration date.
Why periodic reauthorization is necessary, not optional
Unlike annual appropriations, which fund an agency’s operations for a fiscal year and must be renewed every year regardless, SBIR/STTR authorization is a separate, longer-cycle statutory question: does the agency have the underlying legal authority to run the set-aside program at all, and for how long. A lapse in authorization is distinct from a lapse in appropriations (a government shutdown) — an authorization lapse can occur even when the government is otherwise fully funded and open, and a shutdown can occur independently of where SBIR/STTR authorization stands. Institutions sometimes conflate the two; they are governed by different statutes and different triggers, and either one alone can disrupt a pending SBIR/STTR proposal.
This periodic-renewal design is not unique to SBIR/STTR, but it matters more here than for most research funding mechanisms because SBIR/STTR is the primary non-dilutive, milestone-based federal funding path for early-stage, small-business-led R&D commercialization — including a substantial share of university spinouts working through technology transfer licensing arrangements. A lapse doesn’t just delay one grant cycle; it stalls the specific funding mechanism many faculty-founder startups are depending on to bridge from a university invention disclosure to a commercially viable product.
The current reauthorization status (as of mid-2026)
The most recent multi-year reauthorization before the current one was the SBIR and STTR Extension Act of 2022 (Public Law 117-183), signed September 30, 2022 — the same day the prior authorization was set to expire — which extended SBIR, STTR, and several related pilot programs for three years, through September 30, 2025. That extension added national-security-related due diligence, reporting, and clawback provisions responding to a series of high-profile SBIR fraud cases involving foreign ties.
No reauthorizing legislation was enacted before that September 30, 2025 deadline, and SBIR/STTR statutory authority lapsed. Participating agencies handled the lapse differently but along the same basic lines: no new solicitations, no new awards, existing awards administered but not expanded. NIH, for example, issued Notice NOT-OD-26-006 on November 17, 2025, closing all of its then-open SBIR/STTR funding opportunities effective immediately and stating that active NIH SBIR/STTR awards could continue, but that NIH would not issue noncompeting continuation awards for existing projects until the program was reauthorized; the Department of Defense took a related but distinct approach, pausing rather than formally closing its solicitations and holding upcoming topics in pre-release status while contracting for new Phase I and Phase II awards could not proceed.
The lapse lasted roughly six months. Congress passed the Small Business Innovation and Economic Security Act (S. 3971) — the Senate by voice vote on March 3, 2026, and the House 345–41 on March 17, 2026 — and, per multiple independently corroborating government-contracts law firm client alerts, it was signed into law on April 13, 2026, as Public Law 119-83. [REPORTED, cross-corroborated across several secondary sources; the exact signature date and public law number were not independently confirmed against congress.gov’s own bill-status page this session because that page returned an access error to automated fetching — treat as highly likely accurate given convergence, but verify directly if precision matters for a specific compliance purpose.] The new law is a five-year reauthorization, extending SBIR/STTR statutory authority and required funding levels through September 30, 2031.
Beyond the extension itself, the 2026 reauthorization made several substantive changes worth knowing:
- A new “Strategic Breakthrough” Phase II award category at agencies with large SBIR budgets, reported with an award ceiling around $30 million and a requirement that awardees secure matching non-federal funds — [REPORTED across multiple sources; not independently confirmed against the enacted bill text itself this session].
- A faster decision timeline for these new Strategic Breakthrough awards specifically — agencies are directed to execute them within roughly 90 days of proposal receipt.
- Expanded national-security and foreign-ties due diligence on applicants, building on the 2022 Act’s provisions — examining foreign affiliations, investment ties to countries of concern, and related technology-licensing arrangements.
- Per-company/per-solicitation proposal caps, to be established by individual agencies beginning fiscal year 2027, aimed at so-called “SBIR mills” that submit high volumes of low-quality proposals.
- An extended GAO reporting window, reported as moving from three years to eight years for certain program oversight reporting.
Institutions should treat the specific dollar figures and provision details above as accurate at the level of general direction, verified across converging secondary sources, but should confirm exact figures against SBA’s implementing policy directive and each participating agency’s own solicitation guidance before relying on them for a specific proposal — dollar caps and administrative details are exactly the kind of thing an agency’s implementation guidance can adjust even after the authorizing statute is settled.
What happens administratively during a lapse or extension gap
For a grantee institution — a university sponsored-programs office, a faculty PI, or a small-business partner in an STTR collaboration — an SBIR/STTR authorization lapse has a specific, recurring administrative shape based on how the 2025–2026 lapse actually played out:
- Active, already-funded awards generally continue. A Phase I or Phase II award already made before the lapse does not automatically stop; the agency continues to administer and pay against the existing award instrument. This is the single most important point for an institution to communicate internally during a lapse — a lapse in authorization to make new awards is not the same as a clawback of existing ones.
- Noncompeting continuation awards can stall. Some agencies (NIH’s approach during the 2025–2026 lapse is the documented example) will not issue noncompeting continuation funding for an existing multi-year award until reauthorization occurs, even though the underlying project isn’t otherwise affected. A PI expecting a routine continuation of an already-approved multi-year Phase II budget should not assume it will arrive on schedule during a lapse.
- New solicitations close or pause. Open funding opportunity announcements get formally closed (NIH’s approach) or held in a frozen, pre-release-only state (DoD’s approach) — either way, no new SBIR/STTR competition proceeds during the lapse.
- Submitted-but-not-yet-awarded applications are in limbo, not rejected outright. Applications already received before a solicitation closed may still go through peer review, but cannot result in a funded award until authority is restored — meaning a pending application can sit in a genuinely indeterminate state for months.
- Agencies do not act identically. Because each of the 11 agencies that runs SBIR (and the 5 of those that also run STTR) administers the program under its own solicitation and contracting conventions, a sponsored-programs office managing awards across multiple agencies should check agency-specific guidance rather than assuming NIH’s approach generalizes to NSF, DoD, DOE, or NASA.
- Once reauthorized, agencies resume on their own timelines — reopening solicitations, restarting the review-to-award pipeline, and (under the 2026 law specifically) working toward the new required decision timelines for Strategic Breakthrough awards. Institutions should expect a ramp-up period rather than an immediate return to normal solicitation cadence.
The practical institutional takeaway: a sponsored-programs office’s role during a lapse is mostly about accurate internal communication and expectation-setting — confirming which awards are unaffected, which continuation funding may be delayed, and which pending applications are genuinely paused rather than declined — not about any action the institution itself needs to take to preserve its position. Because SBIR is a small-business-prime program (the small business, not the university, is always the awardee of record — see the SBIR dictionary entry for how that structure works, and how it differs under STTR), a university’s practical exposure during a lapse is usually indirect: a spinout or industry partner’s SBIR/STTR-funded work slows, which can in turn affect a related license agreement, sponsored research agreement, or an STTR subaward the university itself holds.
Why this matters for research administrators and technology transfer offices
SBIR/STTR reauthorization risk is a recurring planning input, not a one-time event to track and forget. The programs have now lapsed and been restored at least twice in recent years (most recently 2025–2026; the 2022 Act’s last-minute signature on its own expiration date is itself evidence of how close to the deadline reauthorization routinely runs), and the underlying structural exposure — a fixed-term authorization that requires affirmative congressional action to renew — hasn’t changed even though the current authorization now runs through September 30, 2031. For a technology transfer office advising a faculty founder, or a sponsored-programs office supporting an STTR partnership, that means:
- Treat SBIR/STTR-dependent commercialization timelines (alongside NSF I-Corps and other early-stage translational funding) as carrying reauthorization risk in any multi-year plan that extends close to the current expiration date, and build in a contingency conversation well before September 30, 2031.
- Distinguish, in any internal guidance, between an authorization lapse (what this page covers) and an appropriations lapse (a government shutdown) — they are governed separately and can occur independently, and conflating them in guidance to faculty and industry partners creates confusion about what is and isn’t actually affected.
- Watch agency-specific notices (NIH’s Guide for Grants and Contracts, individual agency SBIR/STTR program pages, and sbir.gov) directly rather than relying on general news coverage, since — as the 2025–2026 lapse showed — agencies do not all respond identically or on the same timeline.
Frequently asked questions
Is SBIR currently authorized?
Yes, as of this page’s verification date. SBIR/STTR statutory authority lapsed on September 30, 2025 and was restored by the Small Business Innovation and Economic Security Act (S. 3971), reported signed into law April 13, 2026, extending authorization through September 30, 2031. Confirm current status directly against sbir.gov or congress.gov if you are reading this page close to or after that expiration date.
What happens to an existing SBIR or STTR award if authorization lapses?
Based on how the 2025–2026 lapse was actually administered, an award already made generally continues to be funded and administered, but a noncompeting continuation for a later budget period of that same award can be delayed until reauthorization occurs. New awards and new solicitations stop until authority is restored.
How is an SBIR/STTR authorization lapse different from a government shutdown?
An authorization lapse means the underlying statute permitting agencies to run the SBIR/STTR set-aside program has expired and must be renewed by separate legislation. A government shutdown is a lapse in annual appropriations. The two are governed by different statutes and different triggers, and either can occur without the other — an institution should track them separately rather than assuming one implies the status of the other.
How often does SBIR/STTR need to be reauthorized?
There is no fixed interval set in the founding statutes; each reauthorization act sets its own term. Recent reauthorizations have run in the range of a few years to five years — the 2022 Act ran three years (through September 30, 2025), and the 2026 Act runs five years (through September 30, 2031). Institutions should treat the current expiration date as the relevant planning horizon rather than assuming a standard cycle length.
Related CASRAI resources
For the program’s core structure — eligibility, the three-phase model, and how SBIR and STTR differ from each other — see the SBIR dictionary entry. For adjacent early-stage commercialization and technology-transfer mechanics that interact with SBIR/STTR-funded work, see the NSF I-Corps guide, provisional patent applications, and iEdison invention reporting. For the general federal cost-principles framework governing how any federal award (SBIR/STTR included, subject to each agency’s specific implementation) is administered post-award, see Uniform Guidance (2 CFR 200). For the broader grants-management picture, see the Grants Management & Research Funding pillar and the Technology Transfer & Innovation pillar.
